It is noteworthy that response rates for achieving PASDAS LDA and MDA increased over time across subgroups, including those with characteristics that have been associated with reduced efficacy with other PsA treatments (i.e., female sex, obesity, and CRP level) [4, 5, 7], as well as patients with more active skin and joint disease at baseline. The gene discussed is CRP; the disease is obesity disorder.